Instituto Valenciano de Oncologia-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2021

  1. Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project

    European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284

2017

  1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2015

  1. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial

    The Lancet Oncology, Vol. 16, Núm. 8, pp. 928-936

2013

  1. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2010

  1. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

    Journal of the National Cancer Institute, Vol. 102, Núm. 20, pp. 1547-1556

2007

  1. Treatment guidelines in ovarian cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 5, pp. 308-316

2003

  1. Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

    Annals of Oncology, Vol. 14, Núm. 3, pp. 441-448

  2. Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643

2001

  1. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: An EORTC gynaecological cancer cooperative group study

    Gynecologic Oncology, Vol. 81, Núm. 3, pp. 348-354

2000

  1. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158

1999

  1. UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

    ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40

1996

  1. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial

    Annals of Oncology, Vol. 7, Núm. 6, pp. 581-585

1995

  1. A phase II trial of weekly high dose continuous infusion 5‐fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

    Cancer, Vol. 76, Núm. 4, pp. 559-563